Investigator Initiated Research

With the outbreak of 2019-nCoV Acute Respiratory Disease (COVID-19), Lilly is monitoring closely this rapidly evolving global health crisis. Although our Investigator Initiated Research (IIR) Portal is open and we continue to process submissions, we are sensitive to the burden of COVID-19 globally and understand if there is a need to slowdown the application process. The safety and wellbeing of patients remain our highest priority.


SPECIAL NOTE REGARDING BARICITINIB

Lilly is committed to support the understanding of baricitinib’s potential use for the treatment of COVID-19. We have begun investigating baricitinib as a potential treatment for COVID-19 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). In addition, Lilly is already collaborating on a significant number of Investigator-led trials on this topic. With these significant efforts underway to understand the role of baricitinib in COVID-19 Lilly has decided to no longer accept new IIT submissions, related to treatment of COVID-19 with baricitinib until we see controlled data on the use of baricitinib. Lilly will continue evaluating proposals for treatment of COVID-19 not related to baricitinib.


In addition to sponsoring its own research and research collaborations, Lilly has programs for considering external requests for Lilly provision of study drug and/or financial support for Investigator Initiated Research that is initiated, designed and sponsored by external researchers. Lilly considers such requests for support of Investigator Initiated Research projects based on scientific merit and strategic fit with Lilly’s areas of research interest. These reviews are carried out by global committees comprised of Lilly medical and scientific staff members from relevant therapeutic areas.

This site is intended for Health Care and Research Professionals over the age of 18.

The Concept to Trial Process
  • Concept

    A simple description of the study idea in 1,000 characters or less. If in scope, the concept will move to the proposal stage.

  • Proposal

    Once deemed in scope, submit a proposal with more details about the proposed research.

  • Protocol

    For clinical studies, provide all study details.

  • Study Readiness

    Activities such as contracting, budgeting, ethics review, and drug shipping.

  • Active Trial

    The study is executed according to the protocol and contract.

Submit a Concept

After submitting your initial concept in the form below,
Lilly will review the concept and get back to you within 10 business days.

If you do not see your country listed, please select “Other” as your country and designate your country below in the Summary Description

If you do not see your compound listed, please select “Other” as your compound and indicate the compound in the Summary Description

By completing this form and clicking submit, you agree to the Privacy Statement linked to this site and are consenting to have your e-mail address and personal information you have provided to be collected and used by Eli Lilly and Company and its affiliates and representatives for processing your request for Investigator Initiated Research. Your information will be retained within a secure environment at Lilly.

Your Session will expire in 15 minutes. Click on Ok button to extend the session or Logout button to redirect to Login Page.